These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 21844324)

  • 21. Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy.
    Mariné M; Pastor FJ; Sahand IH; Pontón J; Quindós G; Guarro J
    Antimicrob Agents Chemother; 2009 Dec; 53(12):5297-9. PubMed ID: 19786599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera.
    Wiederhold NP; Najvar LK; Bocanegra R; Molina D; Olivo M; Graybill JR
    Antimicrob Agents Chemother; 2007 May; 51(5):1616-20. PubMed ID: 17307976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.
    Andes D; Diekema DJ; Pfaller MA; Bohrmuller J; Marchillo K; Lepak A
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2497-506. PubMed ID: 20385855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole.
    Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2005 Nov; 43(11):5425-7. PubMed ID: 16272464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low but sufficient anidulafungin exposure in critically ill patients.
    van Wanrooy MJ; Rodgers MG; Uges DR; Arends JP; Zijlstra JG; van der Werf TS; Kosterink JG; Alffenaar JW
    Antimicrob Agents Chemother; 2014; 58(1):304-8. PubMed ID: 24165173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro synergy of echinocandins with triazoles against fluconazole-resistant Candida parapsilosis complex isolates.
    Ahmadi A; Mahmoudi S; Rezaie S; Hashemi SJ; Dannaoui E; Badali H; Ghaffari M; Aala F; Izadi A; Maleki A; Meis JF; Khodavaisy S
    J Glob Antimicrob Resist; 2020 Jun; 21():331-334. PubMed ID: 31715297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.
    Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2008 Jan; 46(1):150-6. PubMed ID: 18032613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method.
    Arévalo MP; Carrillo-Muñoz AJ; Salgado J; Cardenes D; Brió S; Quindós G; Espinel-Ingroff A
    J Antimicrob Chemother; 2003 Jan; 51(1):163-6. PubMed ID: 12493803
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Postantifungal effect of anidulafungin against Candida albicans, Candida dubliniensis, Candida africana, Candida parapsilosis, Candida metapsilosis and Candida orthopsilosis.
    Gil-Alonso S; Quindós G; Eraso E; Jauregizar N
    Rev Esp Quimioter; 2019 Apr; 32(2):183-188. PubMed ID: 30847462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis.
    Pfaller MA; Diekema DJ; Boyken L; Messer SA; Tendolkar S; Hollis RJ; Goldstein BP
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4795-7. PubMed ID: 16251335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of anidulafungin in pleural fluid during the treatment of a patient with Candida empyema.
    Moriyama B; Ditullio M; Wilson E; Henning SA; Penzak SR; Danner RL; Pennick G; Rinaldi MG; Zelazny AM; Gea-Banacloche J; Barrett AJ; Walsh TJ
    Antimicrob Agents Chemother; 2011 May; 55(5):2478-80. PubMed ID: 21402857
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata.
    Spreghini E; Orlando F; Sanguinetti M; Posteraro B; Giannini D; Manso E; Barchiesi F
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1215-22. PubMed ID: 22203604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods.
    Montagna MT; Lovero G; Coretti C; Martinelli D; De Giglio O; Iatta R; Balbino S; Rosato A; Caggiano G
    BMC Microbiol; 2015 May; 15():106. PubMed ID: 25990252
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disk diffusion-based methods for determining Candida parapsilosis susceptibility to anidulafungin.
    Odabasi Z; Paetznick V; Goldstein BP; Rex JH; Ostrosky-Zeichner L
    Antimicrob Agents Chemother; 2003 Sep; 47(9):3018-20. PubMed ID: 12937018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies.
    Cantón E; Espinel-Ingroff A; Pemán J; del Castillo L
    Antimicrob Agents Chemother; 2010 May; 54(5):2194-7. PubMed ID: 20145083
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies.
    Kontoyiannis DP; Bassetti M; Nucci M; Capparella MR; Yan JL; Aram J; Hogan PA
    Mycoses; 2017 Oct; 60(10):663-667. PubMed ID: 28597967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Anidulafungin: a new echinocandin for the treatment of mycosis].
    Del Palacio A
    Rev Iberoam Micol; 2008 Jun; 25(2):74-7. PubMed ID: 18473500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp.
    Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Jones RN; Turnidge J; Diekema DJ
    J Clin Microbiol; 2010 Jan; 48(1):52-6. PubMed ID: 19923478
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts.
    Howard SJ; Livermore J; Sharp A; Goodwin J; Gregson L; Alastruey-Izquierdo A; Perlin DS; Warn PA; Hope WW
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4880-7. PubMed ID: 21807969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent advances in the management of invasive candidiasis: role of anidulafungin.
    Viscoli C
    Drugs; 2009; 69 Suppl 1():1-3. PubMed ID: 19877727
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.